



NDA 18564/S-062
NDA 19345/S-047
NDA 18562/S-059
NDA 18563/S-060
NDA 18561/S-060

SUPPLEMENT APPROVAL

ICU Medical, Inc.
Attention: Amy Giertych
Vice President, Quality Assurance and Regulatory Affairs
600 North Field Dr.
Lake Forest, IL 60045

Dear Ms. Giertych:

Please refer to your Supplemental New Drug Applications (sNDA) dated and received September 19, 2017, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

NDA	Supplement	Product Name
18564	S-062	20% Dextrose Injection
19345	S-047	30 % Dextrose Injection
18562	S-059	40% Dextrose Injection
18563	S-060	50% Dextrose Injection
18561	S-060	70% Dextrose Injection

These Prior Approval supplemental new drug applications provide for clarifications to the following sections of the Prescribing Information regarding dextrose being derived from corn and patients with known hypersensitivity to dextrose (Contraindications, Warnings and Precautions (5.2), Description).

APPROVAL & LABELING

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA

NDA 18564/S-062
NDA 19345/S-047
NDA 18562/S-059
NDA 18563/S-060
NDA 18561/S-060
Page 2

automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling, with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Heather Buck, Regulatory Project Manager, at (301) 796-1413.

Sincerely,

{See appended electronic signature page}

Joyce Korvick, M.D., M.P.H.
Deputy Director for Safety
Division of Gastroenterology and Inborn Errors Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling (Prescribing Information)

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOYCE A KORVICK
05/14/2018